Zydus to Acquire 85.6% Stake in France-Based Amplitude Surgical

Zydus Lifesciences Limited, a global innovation-driven life sciences company, began exclusive negotiations to acquire an 85.6 percent stake in Amplitude Surgical, whereby the deal is proposed by PAI Partners, Amplitude Surgical's management, and two minority shareholders for €6.25 a share.

The bid provides an 80.6 percent premium to Amplitude Surgical's closing price of €6.25 on March 10, 2025; it also represents an 88.2 percent and a 92.2 percent premium with respect to its three-month and six-month volume-weighted average prices, respectively.

Amplitude Surgical is among the foremost European MedTech companies fully focused on providing high-quality technologies in the fields of orthopedic lower limb surgery. The company designs and develops knee and hip prostheses to replace joints that have been rendered dysfunctional or perforated.

Within the support of PAI Partners behind the company, Amplitude Surgical was able to grow very substantially over the last four years with an entirely different focus positioned toward an array of new product designs, international expansion, and increased investments in manufacturing and R&D.

For the financial year ending June 30, 2024, consolidated sales of Amplitude Surgical came in at €106 million and EBITDA at €27.1 million, according to the IFRS. By the end of the six-month period on December 31, 2024, the company posted €51.5 million in sales, indicating a 5 percent drop year-on-year, with the projected EBITDA margin resting at 25.4 percent.

"Our legacy in science, health and innovation has enabled a deep understanding of patient journey and their care pathways. We believe this was a natural extension in the field of medical technology. Our commitment to quality excellence, continuous investments in R&D and expertise in manufacturing will guide our foray into highly specialised MedTech products, adding a new dimension to our operations. In Amplitude Surgical, we see several medium-term and long-term growth opportunities with respect to portfolio, capabilities, manufacturing and geographies", said Dr. Sharvil Patel, Managing Director, Zydus Lifesciences Limited.

Zydus MedTech is a company delivering high-quality medical solutions through advanced research, design, and engineering; manufacturing interventional cardiology products today while expanding its capacity with a specialized team.

"The Amplitude Surgical team and I are delighted to join Zydus. This acquisition by a worldwide healthcare leader is a testament to the successful development of the Company over the last 25+ years, originally as a national orthopedics challenger and today as a European leader. I would like to thank PAI Partners for their trust and continuous support in our growth journey. We have demonstrated our resilience in periods of uncertainty while driving the transformation of the Company, developing our commercial, industrial, and technological capabilities", added Olivier Jallabert, CEO and Founder, Amplitude Surgical.